Executive Interview – NeuroVive Pharmaceutical

Published on 29 November 2017

NeuroVive is a leader in mitochondrial medicine, with one project in clinical Phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical Phase I (KL1333) for genetic mitochondrial diseases. Here, CEO Erik Kinnman speaks about the company as it stands now and what the future holds for it.

Please click here to watch Part 2, or here to watch Part 3.

Share this with friends and colleagues